Executive Vice President and Group President, Medtronic Diabetes
Hooman Hakami was named Executive Vice President and Group President of Medtronic Diabetes in June of 2014. Hooman provides overall strategic direction and operational management of the Group’s three global business units.
Hooman came to Medtronic after more than 20 years at General Electric. He was President and CEO of Detection & Guidance Solutions at GE Healthcare from April 2012 until May 2014. In that role he led that company’s business specializing in x-ray based technology solutions. Previously he served as President and CEO of the Interventional Systems business based in France, and the Global Clinical Systems Services for GE Healthcare.
Hooman received his Bachelor in Business Administration degree in operations management from the University of Massachusetts, where he graduated cum laude in 1991. Away from work he enjoys travel, sports, and spending time with his family.
I’m excited to announce a new patient-centric partnership which will expand access to our therapies to people living with diabetes in Asia Pacific (APAC). We are partnering with the world’s largest diabetes out-patient hospital – the Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders (BIRDEM) – to drive positive health outcomes […]Read More »
Today we announced an outcomes-based agreement with Aetna for type 1 and type 2 diabetes patients who currently receive multiple daily insulin injections for their diabetes management. The agreement will measure health outcomes for those patients that choose to transition to pump therapy using a Medtronic insulin pump featuring SmartGuard™ Technology – the only feature […]Read More »
I received a very touching email from one of our employees a few weeks ago. Key is a technical writer in Northridge, and is currently on the MiniMed 670G system as part of the Customer Training Phase. Key has graciously agreed to allow me to share his experience with you; I hope you find his […]Read More »
In December, we held our annual Holiday Program in Minneapolis. Our CEO, Omar Ishrak, says it’s the most important event of the year. It’s a long standing tradition Earl Bakken started many years ago as a way to showcase our Mission. Every year, Medtronic invites patients and physicians who represent many of our business units. […]Read More »
In August, we launched the MiniMed 630G system in the U.S. Some of the first customers on the new system were employees, and among them is Naomi Ruperto, social community manager in Northridge, who has worked at Medtronic for more than seven years. This week, she shares her very positive experience with the new system. […]Read More »
I have wonderful news to share with you today. I am extremely proud to announce that the FDA has just approved our groundbreaking MiniMed 670G system – the first hybrid closed loop system in the world! This approval is a significant milestone in the history of diabetes management, and a culmination of many years of […]Read More »
Hypoglycemia (low blood glucose) can be very dangerous and is one of the most frightening situations for people with diabetes – particularly during the night when an estimated 57% of people with type 1 diabetes experience a low at least once.[i] Not to mention it impacts their quality of life and takes time out of […]Read More »
Expanding access to our therapy to help more people with diabetes is central to our goal of transforming diabetes care for greater freedom and better health. In many parts of the world, insurance does not cover continuous glucose monitoring (CGM), despite clear evidence the technology has clinical and economic benefits. Together, we face a CGM […]Read More »
I am so proud of our employees’ generosity. While we support our communities throughout the year– fundraising and participating in walks for the JDRF and ADA, among other activities and organizations– this year, we had phenomenal participation in Project 6. Project 6 is Medtronic’s month-long global effort to support the sixth tenet of our Mission […]Read More »
Our industry is changing and evolving at an unprecedented rate, which is why it is important for us to set the pace of innovation across several areas. Disruptive Innovation for Type 1 Diabetes Recently, we shared pivotal trial results for the first hybrid closed loop system. I am extremely excited to announce today that we […]Read More »
For more than 30 years, Medtronic Diabetes has been known as an insulin pump and sensor company. While we have made great progress in improving outcomes and care for people with diabetes, we believe we can make a greater impact. This means changing our strategy. We are exploring new models of care, including integrated care […]Read More »
I am very excited to share with you that we are collaborating with Qualcomm Life to develop future-generation continuous glucose monitoring (CGM) systems for people with type 2 diabetes. This collaboration – with an expert in developing reference designs for wireless, single-use and small integrated modules – enables us to create more affordable, easier-to-use professional […]Read More »
No, I’m not referring to the cool movie trilogy starring Keanu Reeves. I’m talking about an organizational model. When we hear “matrix,” the word used to describe an organization, it doesn’t usually evoke positive feelings. Instead, it typically causes anxiety. What seems to concern most people is the dual reporting nature of the matrix. Employees […]Read More »
In January 2016, we signed a long-term partnership with the Chengdu municipal government to provide better diabetes management for the growing – and underserved – diabetes population in China. So, why China? According to the International Diabetes Federation, there are 415 million people in the world living with diabetes.[i] That’s a staggering number. Twenty-five million […]Read More »
A couple months ago, I had a very interesting evening at a dinner in London with the Medtronic Board of Directors, members of the Executive Committee, senior leaders, and physicians from some of the most prestigious hospitals in the United Kingdom (UK), as well as members of the National Health Service. The dinner was set […]Read More »
I am excited to announce Diabetes, Obesity and Metabolism, an international, peer-reviewed journal, recently published the results of the continuation phase of our OpT2mise study, which could redefine the standard of care and expand access to insulin pump therapy for the growing population of insulin-dependent people with type 2 diabetes with poor glucose control. Our […]Read More »